Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 47Genitourinary 43Other hematologic neoplasm 12Plasma cell 7Myeloid 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Trastuzumab 86Cyclophosphamide 67Capecitabine 67Paclitaxel 63Docetaxel 57Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 40Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 18atezolizumab 17Everolimus 17130-nm albumin-bound paclitaxel 17pertuzumab 16Epirubicin 16palbociclib 15eribulin 14Magnetic Resonance Spectroscopy 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Prednisone × Breast × Clear all
NCT04726332 2024-05-14

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Exelixis

Phase 1 Terminated
52 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡